Bloomberg Kimmel Institute for Cancer Immunotherapy » Johns Hopkins Drug Discovery
1793
page-template,page-template-full_width,page-template-full_width-php,page,page-id-1793,page-child,parent-pageid-23,bridge-core-3.0.5,qi-blocks-1.0.5,qodef-gutenberg--no-touch,qodef-qi--no-touch,qi-addons-for-elementor-1.5.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-29.1,qode-theme-bridge,disabled_footer_bottom,wpb-js-composer js-comp-ver-6.9.0,vc_responsive,elementor-default,elementor-kit-3247,x-shortcodes-v3_0_5

Bloomberg Kimmel Institute for Cancer Immunotherapy

Bloomberg~Kimmel Institute for Cancer Immunotherapy

The Bloomberg~Kimmel Institute for Cancer Immunotherapy led by Dr. Drew Padroll is at the forefront of discovering and developing new immune-based cancer treatments. The institute builds on pioneering discoveries, many here at Johns Hopkins, that are making it possible to trigger the immune system’s innate cancer-fighting abilities. The JHDD plays an integral part of the Bloomberg~Kimmel Institute for Cancer Immunotherapy by serving as its Drug Discovery and Development Core, which provides a broad range of expertise in drug discovery research to translate findings from basic and clinical research into novel cancer immunotherapy.